CHACladribine, Homoharringtonine and Cytarabine (CHA) Regimen for Adult Acute Myeloid Leukemia Remission

This study focuses on a new chemotherapy regimen called CHA, which is a combination of cladribine, homoharringtonine, and cytarabine. The purpose of this regimen is to induce remission in adults diagnosed with a type of blood cancer known as acute myeloid leukemia. The study aims to evaluate the effectiveness and safety of this new treatment approach. The importance of this study lies in its potential to improve the care and outcomes for patients with this specific form of leukemia. Participants in this study will receive the CHA regimen, with specific dosages and durations for each drug. Treatment response will be assessed after each cycle, and further treatment will be determined based on these responses. If a patient achieves more than a partial remission in the first course, the CHA regimen is repeated. If a partial response is not achieved in the first course, or a complete response is not achieved in the second course, the patient will be withdrawn from the study. The study measures the results by evaluating bone marrow samples and assessing the response according to the Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Potential risks and benefits will be evaluated as part of the study.